Precision medicine such as the combination of dabrafenib and trametinib in BRAF V600E mutated gliomas, or other tyrosine kinase inhibitors such as regorafenib or NTRK inhibitors, may be used in selected patients. This evidence concerns the gene BRAF and glioma.